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Background. It is unclear whether immunosuppression leads to younger ages at cancer diagnosis among people living with 
human immunodeficiency virus (PLWH). A previous study found that most cancers are not diagnosed at a younger age in people 
with AIDS, with the exception of anal and lung cancers. This study extends prior work to include all PLWH and examines associa-
tions between AIDS, CD4 count, and age at cancer diagnosis.
Methods. We compared the median age at cancer diagnosis between PLWH in the North American AIDS Cohort Collaboration 
on Research and Design and the general population using data from the Surveillance, Epidemiology and End Results Program. We 
used statistical weights to adjust for population differences. We also compared median age at cancer diagnosis by AIDS status and 
CD4 count.
Results. After adjusting for population differences, younger ages at diagnosis (P < .05) were observed for PLWH compared with 
the general population for lung (difference in medians = 4 years), anal (difference = 4), oral cavity/pharynx (difference = 2), and 
kidney cancers (difference = 2) and myeloma (difference = 4). Among PLWH, having an AIDS-defining event was associated with 
a younger age at myeloma diagnosis (difference = 4; P = .01), and CD4 count <200 cells/µL (vs ≥500) was associated with a younger 
age at lung cancer diagnosis (difference = 4; P = .006).
Conclusions. Among PLWH, most cancers are not diagnosed at younger ages. However, this study strengthens evidence that 
lung cancer, anal cancer, and myeloma are diagnosed at modestly younger ages, and also shows younger ages at diagnosis of oral 
cavity/pharynx and kidney cancers, possibly reflecting accelerated cancer progression, etiologic heterogeneity, or risk factor expo-
sure in PLWH.
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People living with human immunodeficiency virus (PLWH) are 
at increased risk of several cancer types, including those con-
sidered to be AIDS-defining events (ie, Kaposi sarcoma, cer-
tain non-Hodgkin lymphomas, and invasive cervical cancer), 
as well other types of cancer, particularly anal, lung, and liver 
cancers, and Hodgkin lymphoma [1]. Effective antiretroviral 
therapy (ART) has decreased AIDS-defining cancer rates and 
increased survival of PLWH [2]. The longevity afforded by ART 
has resulted in an increased burden of non-AIDS-defining can-
cers over time [3, 4].
Some reports have noted that the age at cancer diagnosis is 
10–20  years younger among PLWH compared with the gen-
eral population across a number of cancers [5–10]. However, 
the proportion of PLWH who are middle-aged or older (ie, age 
groups at greatest cancer risk) is far smaller than in the general 
US population (eg, 4.0% vs 13.0% aged ≥65 years in 2010) [11, 
12]. Apparent earlier ages at non-AIDS-defining cancer diagno-
sis in persons with AIDS are primarily explained by differences 
in the underlying populations at risk [13], with no evidence of 
a general acceleration of cancer development. However, mod-
est but statistically significantly younger ages at lung and anal 
cancer diagnosis, and older ages at Hodgkin lymphoma diagno-
sis compared with the general population, have been reported 
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[13]. As this prior study was limited to people with AIDS (ie, 
advanced HIV disease), more studies are needed to characterize 
the age at cancer diagnosis in all PLWH, and to assess whether 
immunosuppression plays a role in accelerated cancer develop-
ment as evidenced by younger ages at diagnosis.
In this study, we sought to confirm previous findings in a 
different study population and further explore the influence 
of immunosuppression on age at cancer diagnosis among 
all PLWH. We utilized data from 88 018 PLHW in the North 
American AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD), which includes people at all stages of HIV 
infection with CD4 cell counts longitudinally measured. We 
compared age at cancer diagnosis between PLWH and the gen-
eral population, accounting for differences in the underlying 
populations, and then compared age at diagnosis among PLWH 
by AIDS status and CD4 count.
METHODS
NA-ACCORD, a multisite consortium of clinical and inter-
val cohorts in the United States and Canada [14], is the North 
American region of the International Epidemiologic Databases 
to Evaluate AIDS (IeDEA) initiative. Cohorts submit demo-
graphic and clinical data on PLWH (≥18 years old) using stand-
ardized data collection methods. NA-ACCORD was approved 
by institutional review boards at each contributing site. The 
current analysis included PLWH in 16 participating cohorts 
during 1996–2008 (Supplementary Table  1). Person-time for 
ages <20 and ≥80 years was excluded due to sparse data. As only 
birth year is collected, all birth dates were assigned as 1 July.
Cancer Diagnoses in NA-ACCORD and the General Population
Analysis of age at cancer diagnosis was restricted to the 13 most 
common non-AIDS-defining cancers (Table 2). Analysis of mel-
anoma was restricted to white individuals, and breast and pros-
tate cancers were restricted to women and men, respectively. In 
a subanalysis, oral cavity/pharynx cancer was further divided 
into sites most likely to be human papillomavirus (HPV) related 
and HPV unrelated [15]. Individual cohorts validated can-
cer diagnoses through medical records, pathology reports, or 
linkage with cancer registries [16]. For each cancer site, PLWH 
contributed person-time from the latter of 1 January 1996 or 
enrollment into NA-ACCORD until the first of cancer diagno-
sis, death, or 31 December 2008. Only the first primary cancer 
diagnosis of each type was considered.
AIDS onset was defined based on clinical criteria (ie, did not 
include CD4 counts <200 cells/µL without an AIDS-defining 
illness) [17]. CD4 cell counts were assigned as the measurement 
prior to cancer diagnosis.
Cancer data for the general population were derived from 
13 population-based cancer registries in the National Cancer 
Institute’s Surveillance Epidemiology and End Results (SEER) 
program during 1996–2008. Cancer sites were defined according 
to the International Classification of Diseases for Oncology, Third 
Edition [18].
Statistical Analysis
Initially, the unadjusted median age at diagnosis for each can-
cer site was compared between PLWH (NA-ACCORD) and the 
general population (SEER). Weights were then computed to 
weight the SEER population to mirror the characteristics of the 
NA-ACCORD population. Specifically, weights for the SEER 
population were computed as (person-years in NA-ACCORD/
person-years in SEER), in strata defined by single year of age, 
race (white/non-white), and calendar time (1996–1999, 2000–
2003, 2004–2008). The weights were then standardized to the 
total number of cancer cases in the SEER population. We then 
calculated the weighted median age at diagnosis in the general 
population and compared it to the observed ages in PLWH in 
NA-ACCORD using a Mood test with weights implemented in 
“survey” package in R [19]. A sensitivity analysis was restricted 
to men, as data were sparse for women.
Additionally, standardized incidence ratios (SIRs) were 
estimated across 10-year age groups to show the relative risk 
of cancer in PLWH compared to the general population. SIRs 
compare numbers of cancer cases observed in PLWH with 
expected cases, calculated by applying SEER cancer rates to the 
HIV population (ie, person-years) stratified by age (5-year cat-
egories), sex, race, and calendar year. A younger median age at 
diagnosis in PLWH would correspond with SIRs that are higher 
at younger ages. A P value for ordinal trend in SIRs across ages 
was estimated with Poisson regression.
For cancers that occurred at significantly younger ages 
among PLWH in weighted analyses, median ages at diagnosis 
among PLWH were compared by AIDS and recent CD4 count 
(<200, 200–499, ≥500 cells/µL). Each stratum was weighted to 
the entire NA-ACCORD population using the same weighting 
approach described above. Therefore, each weighted group had 
the same distribution of age, race, and calendar period as the 
full NA-ACCORD population. Analyses were carried out using 
SAS version 9.3 (SAS Institute, Cary, North Carolina) and R 
version 3.1.2 (R Project, Vienna, Austria).
RESULTS
Characteristics of 88 018 PLWH in NA-ACCORD who contrib-
uted to this analysis are presented in Table 1. In brief, 86% of 
the person-time was contributed by men, 45% by whites, and 
41% by blacks. The most common specified HIV transmission 
risk group was injection drug users (28% of person-time), but 
a sizeable proportion had unknown HIV risk factors (37%). 
Most person-time was among those without AIDS (75%) and 
those on ART (75%). Twenty-five percent of person-time was 
contributed by PLWH with a CD4 count ≥500 cells/µL, 31% 
with a CD4 count of 200–499 cells/µL, and 15% with a CD4 
count <200 cells/µL; however, 30% of person-time had missing 
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measurements. Among PLWH, 22% of the person-time was 
contributed by 20- to 39-year-olds, 67% by 40- to 59-year-olds, 
and 11% by 60- to 79-year-olds, whereas the corresponding 
proportions in the general population were 45%, 39%, and 18% 
(Figure 1).
In unadjusted analyses, PLWH were 7 years older at Hodgkin 
lymphoma diagnosis than the general population (P  <  .0001; 
Table 2), but the median age at diagnosis for all other cancer 
sites was substantially younger among PLWH (age difference: 
6–14 years; all P < .0001).
After weighting the general population to have the identical 
distribution of age, race and calendar period as NA-ACCORD, 
there was no statistically significant difference in median age at 
diagnosis for 8 cancer types. Small but statistically significantly 
younger ages at diagnosis were observed for PLWH compared 
with the general population for lung (median, 54 vs 58 years), 
anal (47 vs 51), oral cavity/pharynx (51 vs 53), and kidney can-
cers (52 vs 54) and myeloma (52 vs 56; all P <  .05). A 1-year 
difference was observed for both HPV-related (52 vs 53 years; 
P  =  .03) and HPV-unrelated (51 vs 52; P  =  .14) oral cavity/
pharynx cancer sites. A  sensitivity analysis restricted to men 
was consistent with the overall results, with the exception of a 
significantly younger median age at melanoma diagnosis (49 vs 
54 years; P = .0009).
Overall SIRs were significantly elevated for lung (SIR, 2.21; 
95% confidence interval [CI], 2.04–2.38), anal (SIR, 32.0; 95% 
CI, 28.4–35.9), and oral cavity/pharynx cancer (SIR, 1.90; 95% 
CI, 1.63–2.21) and myeloma (SIR,  1.35; 95% CI, 1.00–1.79), 
but not kidney cancer (SIR, 1.16; 95% CI, .96–1.40). The SIRs 
declined significantly with increasing age for each of these can-
cers (all P for trend < .05), indicating that cancer risk in PLWH 
was more strongly elevated at younger ages (Figure  2). There 
were significant elevations across all ages for lung, anal, and oral 
cavity/pharynx cancers, with the exception of 70- to 79-year-
olds for lung and oral cavity/pharynx cancers. In contrast, SIRs 
for kidney cancer were not elevated or only somewhat elevated 
for 30- to 39-, 40- to 49-, and 50- to 59-year-olds and reduced 
among 60- to 69- and 70- to 79-year-olds. Myeloma risk was 
only increased among 30- to 39-year-olds.
After standardization to the entire NA-ACCORD, the age at 
diagnosis was significantly younger among people with AIDS 
compared with people with HIV for myeloma only (50 vs 54; 
P = .01; Figure 3), and a CD4 count <200 cells/µL was associated 
with a significantly younger median age at diagnosis for lung 
cancer only (vs 200–499 cells/µL: 51 vs 55, P = .008; ≥500 cells/
µL: 51 vs 55, P = .006).
DISCUSSION
Using data from the largest consortium of HIV cohorts in 
North America, we showed there is not a broad accelera-
tion in the development of cancer among PLWH manifest-
ing as younger ages at cancer diagnosis across cancer types. 
Nonetheless, after adjustment for population differences in 
age, race, and calendar period, PLWH were diagnosed with 
lung, anal, oral cavity/pharynx, and kidney cancers and mye-
loma at modestly younger ages than the general population. 
Further, among PLWH, the median age at myeloma diagnosis 
was younger among people with AIDS and the median age at 
lung cancer diagnosis was younger among people with CD4 
counts <200 cells/µL, suggesting a potential role of more pro-
found immunosuppression in the accelerated development of 
these cancers.
Table 1. Characteristics of HIV-Infected Participants in the North Amer-
ican AIDS Cohort Collaboration on Research and Design (NA-ACCORD), 
1996–2008
Characteristic Person-years of Follow-up, No. (%)
Sex
 Male 419 557 (85.8)
 Female 69 687 (14.2)
Age, y
 20–29 21 992 (4.5)
 30–39 110 278 (22.5)
 40–49 189 496 (38.7)
 50–59 125 302 (25.6)
 60–69 33 382 (6.8)
 70–79 8793 (1.8)
Race
 White 218 980 (44.8)
 Black 199 809 (40.8)
 Other/unknown 70 455 (14.4)
Risk group
 MSM 110 505 (22.6)
 IDU 136 233 (27.8)
 Heterosexual 57 625 (11.8)
 Other 6493 (1.3)
 Unknowna 178 388 (36.5)
Calendar period
 1996–1999 88 680 (18.1)
 2000–2003 163 830 (33.5)
 2004–2008 236 734 (48.4)
AIDS status
 No 365 853 (74.8)
 Yes 123 391 (25.2)
Ever ART use
 No 121 008 (24.7)
 Yes 368 235 (75.3)
CD4 cell count, cells/µL
 Missingb 146 019 (29.8)
 <200 71 784 (14.7)
 200–499 150 447 (30.8)
 ≥500 120 934 (24.7)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection 
drug user; MSM, men who have sex with men; NA-ACCORD, North American AIDS Cohort 
Collaboration on Research and Design.
aA large fraction of the data in the unknown risk group category come from a single 
NA-ACCORD cohort, the Veterans Aging Cohort Study and Virtual Cohort, which does not 
collect risk group.
bCD4 cell counts were ascertained in each calendar year. If CD4 counts were missing, val-
ues were carried forward from the prior year; if no value was available then CD4 counts 
were set to missing for that interval.
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As in previous work, large apparent differences in age at 
diagnosis for many cancers were driven by dramatic differ-
ences in the underlying age distributions of the HIV-infected 
and general populations [13]. Although more PLWH are 
living to older ages, at present only 4% of the US HIV pop-
ulation is ≥65  years old, compared with 13% in the gen-
eral population [11, 12]. Similarly, only 5% of PLWH in the 
Canadian Observational Cohort Collaboration are ≥65 years 
old (Cescon, unpublished data) compared with 15% in the 
Canadian general population [20]. This smaller fraction of 
PLHW at older ages, when cancer risk is greatest, inherently 
drives down the age at cancer diagnosis relative to the general 
population. To compare median ages at cancer diagnosis in 
an unbiased way, the HIV and general populations must be 
matched or standardized to have an identical underlying age 
distribution [13, 21–23]. An analogous approach is to com-
pare SIRs across age groups, with younger ages at diagnosis 
manifesting as higher SIRs at younger ages.
This study confirmed prior findings of modest, but sta-
tistically significant, younger ages at diagnosis of lung can-
cer, anal cancer, and myeloma among PLWH [13]. Using a 
different methodology from the current study, researchers 
previously reported similar small, but significant, younger 
ages at diagnosis for lung and anal cancer among PLWH 
in the Kaiser Permanente HIV cohort [22] compared with 
matched HIV-uninfected controls. A study using the French 
Hospital Database on HIV observed modestly younger ages 
at diagnosis for lung, but not anal cancer [23]. Although in 
a prior study the younger age at myeloma diagnosis was not 
significant after correction for multiple comparisons, the P 
value was strong (P  =  .004) [13], and considered together 
with the current study we believe there is compelling evi-
dence for replication. In contrast to prior findings [13], 
median age at Hodgkin lymphoma diagnosis was not older 
among PLWH.
Evidence was less clear for several other cancers. Median 
ages at oral cavity/pharynx and kidney cancer diagnosis were 
Table 2. Comparison of Median Ages at Diagnosis Between HIV-Infected People in the North American AIDS Cohort Collaboration on Research and 
Design (NA-ACCORD) and the General Population, After Weighting the General Population to the Age Structure of NA-ACCORD
Observed in HIV-Infected 
Individuals
Observed in  
General Population
General Population  
After Weightinga
Cancer Cases Median Age, y Median Age, y Median Age, y P Value
Lung 644 54 68 58 <.0001
Prostate 504 58 66 59 .43
Anus 291 47 57 51 <.0001
Liver 226 54 62 54 .50
Oral cavity and pharynx 173 51 60 53 .04
Hodgkin lymphoma 171 44 39 45 .98
Colon 111 55 67 56 .55
Kidney 109 52 62 54 .0003
Larynx 86 53 63 56 .09
Melanoma (whites only) 77 49 56 51 .18
Breast 56 48 58 47 .27
Pancreas 55 53.5 67 57 .14
Myeloma 49 52 66 56 .008
Abbreviations: HIV, human immunodeficiency virus; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design.
aThe Surveillance Epidemiology and End Results (SEER) population was weighted to NA-ACCORD population in strata defined by single year of age, calendar period, and race. The P value 
compares the ages in the general population after weighting to the observed ages in HIV-infected individuals in NA-ACCORD.
Figure 1. Fraction of total person-time in the human immunodeficiency virus 
(HIV)-infected population (North American AIDS Cohort Collaboration on Research 
and Design [NA-ACCORD]) and the general population (Surveillance Epidemiology 
and End Results [SEER-13]) by single year of age, 1996–2008. Person-time in the 
HIV-infected population (NA-ACCORD, gray bars) and the general population (SEER-
13, black bars). Bars represent the fraction of person-time contributed by each sin-
gle year of age from 20 to 79 years old.
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2 years younger in PLHW, but the evidence for these cancers is 
weaker, as significant differences were not seen in prior work 
(P  =  .40 and .17, respectively) [13]. Further, SIRs for kidney 
cancer were not elevated in any age group, arguing against a 
biological effect of HIV. Melanoma showed some evidence of 
younger age at diagnosis among men only, but this was not 
observed overall or in a previous study [13].
One possible explanation for modestly younger ages at 
diagnosis for certain cancers in PLWH is that HIV disease 
may slightly accelerate time from the initiation of the car-
cinogenic process to clinical disease due to biological effects 
of immunosuppression, immune activation, and inflamma-
tion. Unlike a prior study that was limited to people with 
AIDS, the present study could assess the association between 
Figure 2. Standardized incidence ratios (SIRs) comparing cancer risk in human immunodeficiency virus-infected people to the general population across age groups for 
lung cancer (A), anal cancer (B), oral cavity and pharynx cancers (C), kidney cancer (D), and myeloma (E). Points represent SIRs and lines represent 95% confidence intervals 
(CIs). SIRs were standardized by age, sex, race, and calendar period. No point is presented for 70- to 79-year-olds in the myeloma figure, as there were no observed cases 
(SIR, 0 [95% CI, 0–.88]).
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immunosuppression and age at cancer diagnosis by exam-
ining AIDS status and CD4 count. Myeloma was diagnosed 
at younger ages among people with AIDS, and lung cancer 
was diagnosed at younger ages among people with current 
CD4 counts <200 cells/µL. For lung cancer and myeloma, the 
inconsistent associations of age at diagnosis with CD4 count, 
a marker of current immune status, and prior AIDS status, 
which captures whether a person ever previously had severe 
immunosuppression, may reflect differences in the timing of 
immunosuppression in relation to the accelerated progression 
of these cancers.
Younger ages at cancer diagnosis may also be due to earlier 
or more intense exposure to key risk factors in PLWH [24]. For 
example, the prevalence of current smoking is 54% in PLWH 
overall and 74% among injection drug users, compared with 
20% in the general population [24]. Furthermore, HIV infection 
is associated with a higher prevalence and persistence of high-
risk anal HPV infections among men who have sex with men 
(MSM), the risk group with the highest anal cancer risk [25]. As 
lung and anal cancers are primarily caused by cigarette smoking 
[26] and high-risk HPV infections [27], respectively, it is pos-
sible that earlier or more intense exposure to cigarette smoking 
and anal HPV could result in younger ages at cancer diagnosis. 
Of note, cigarette smoking also causes oral cavity/pharynx and 
kidney cancers [26], and HIV is associated with a higher prev-
alence of high-risk oral HPV infections, which cause certain 
oropharynx cancers [24, 27]. Earlier and/or greater exposure to 
risk factors may also contribute to an accelerated development 
of these cancers.
Etiologic heterogeneity may play a role in the younger 
age at myeloma diagnosis among PLWH. Myeloma risk was 
increased only among younger PLWH. A similar finding was 
observed among solid organ transplant recipients, another 
immunosuppressed population [28]. One possibility is that 
immunosuppression may increase the risk of rare Epstein-Barr 
(EBV)–positive myelomas, which may have a younger age at 
onset [28]. If HIV increases the risk of EBV-positive earlier-on-
set myeloma, but does not affect the risk of the more common 
EBV-negative myeloma cases that typically occur at older ages, 
a shift to younger ages at myeloma diagnosis would occur 
among PLWH.
Cancer may be diagnosed at somewhat younger ages due to 
increased cancer screening or surveillance among PLWH who 
regularly access medical care. This is not a general phenome-
non, as screen-detectable cancers such as breast, prostate, and 
colon cancers were not diagnosed at younger ages, but it is pos-
sible that our anal cancer finding was driven by an increased 
prevalence of anal Pap testing in PLWH, particularly MSM [29]. 
In contrast, lung cancers are diagnosed at somewhat later stages 
in PLWH [30], potentially reflecting delayed detection, and 
there is no population-wide screening program for myeloma, 
kidney cancer, or oral cavity/pharynx cancer.
Finally, the competing risk of death due to AIDS and other 
causes may contribute to younger ages at diagnosis. If cancer 
Figure 3. Median age at cancer diagnosis by AIDS status (A) and CD4 cell counts (B) for lung cancer, anal cancer, oral cavity and pharynx cancers, kidney cancer, and mye-
loma in human immunodeficiency virus (HIV)-infected people. Points represent median ages at diagnosis and lines represent 95% confidence intervals (CIs). Asterisks indicate 
statistically significant differences in weighted median ages (p<0.05). All estimates were standardized to the full North American AIDS Cohort Collaboration on Research and 
Design (NA-ACCORD) population by single year of age, race, and calendar period. The adjusted median ages at diagnosis for people living with HIV with a missing CD4 cell 
count were 44 years (95% CI, 43–46) for anal cancer, 50 years (95% CI, 46.5–53.0) for kidney cancer, 54 years (95% CI, 53–55.2) for lung cancer, 53 years (95% CI, 49.2–57.5) 
for myeloma, and 51 years (95% CI, 48.4–53) for oral cavity/pharynx cancer.
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and death risk among PLWH are not independent, cancer inci-
dence may be reduced at older ages, which would lead to a 
younger age at diagnosis among observed cases. Although we 
did not account for competing risks in our analysis, the lack 
of younger ages across sites argues against a widespread effect.
The main strength of this analysis was the use of a large con-
sortium of HIV cohorts that included people with and with-
out AIDS, and availability of CD4 counts. In addition, we used 
weighted analyses, correcting the bias induced by comparing 
ages at diagnosis across populations with different distributions 
of age and other characteristics. The main limitation is the lack of 
information on important cancer risk factors, including detailed 
information on smoking and anal HPV infection. Furthermore, 
although most study participants had CD4 cell count data while 
under study, a large fraction of cases were missing prior CD4 cell 
counts. Additionally, SEER data may not be representative of the 
entire US or Canadian population. While our overall findings 
largely replicate prior results [13], some associations (particu-
larly for subgroups) could be the result of chance given multiple 
comparisons. It is important to note that the age at diagnosis is 
just one metric for comparing cancers in PLWH and the gen-
eral population. Although it is an easily understood summary 
measure, it masks relevant information on whether cancer risk 
is elevated and informative patterns in rates across age groups.
Efforts to reduce cancer risk in PLWH are needed to prevent 
many cancer types, regardless of whether age at diagnosis is 
younger. Cancer prevention and early detection is particularly 
important as the number of older PLWH continues to grow [4]. 
These cancer prevention efforts include appropriate initiation 
of ART to prevent AIDS-defining cancers and other immu-
nosuppression-related cancers, facilitation of smoking cessa-
tion, and detection and treatment of hepatitis B and C viruses. 
Furthermore, PLWH should receive age-appropriate cancer 
screening based on general population guidelines. More research 
is needed on screening for lung and anal cancers among PLWH. 
There are no national screening guidelines for anal cancer [31]. 
The ongoing Anal Cancer/HSIL Outcomes Research (ANCHOR) 
Study is examining the benefits of treating precancerous anal 
lesions in PLWH that may be detected through screening 
(National Institutes of Health clinical trials identification num-
ber: NCT02135419). Low-dose computed tomography (LDCT) 
is recommended for the early detection of lung cancer for some 
current and former smokers [32]; however, more data are needed 
on the sensitivity and specificity of LDCT among PLWH.
In summary, although we have confirmed prior findings 
that 3 malignancies (anal cancer, lung cancer, and myeloma) 
develop 3–4  years earlier than in the general population, the 
development of other cancers does not seem to be broadly 
accelerated in PLWH. Additionally, there is some evidence that 
immunosuppression is associated with younger ages at lung 
cancer and myeloma diagnoses. Although there is not a general 
acceleration of cancer development in PLWH, the cancer bur-
den will continue to grow as the population ages, highlighting 
the need for cancer prevention and early detection.
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APPENDIX
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Clinical Trials Group Longitudinal Linked Randomized Trials: 
Constance A. Benson and Ronald J. Bosch; Fenway Health HIV 
Cohort: Stephen Boswell, Kenneth H. Mayer, and Chris Grasso; 
HAART Observational Medical Evaluation and Research: Robert 
S. Hogg, P. Richard Harrigan, Julio SG Montaner, Angela Cescon, 
and Tareq Ahmed; HIV Outpatient Study: Kate Buchacz and 
John T.  Brooks; HIV Research Network: Kelly A.  Gebo and 
Richard D. Moore; Johns Hopkins HIV Clinical Cohort: Richard 
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